Naptumomab estafenatox
Modify Date: 2025-08-25 10:42:24
Naptumomab estafenatox structure
|
Common Name | Naptumomab estafenatox | ||
|---|---|---|---|---|
| CAS Number | 676258-98-3 | Molecular Weight | N/A | |
| Density | N/A | Boiling Point | N/A | |
| Molecular Formula | N/A | Melting Point | N/A | |
| MSDS | N/A | Flash Point | N/A | |
Use of Naptumomab estafenatoxNaptumomab estafenatox (ABR-217620) is a tumor targeting superantigen (TTS). Naptumomab estafenatox is a fusion protein containing an anti-5T4 antibody and a SEA/E-120 superantige. Naptumomab estafenatox can be used for the research of lung cancer[1]. |
| Name | Naptumomab estafenatox |
|---|
| Description | Naptumomab estafenatox (ABR-217620) is a tumor targeting superantigen (TTS). Naptumomab estafenatox is a fusion protein containing an anti-5T4 antibody and a SEA/E-120 superantige. Naptumomab estafenatox can be used for the research of lung cancer[1]. |
|---|---|
| Related Catalog | |
| In Vitro | Naptumomab estafenatox (0.001-10000 pM；4 小时) 对人葡萄球菌肠毒素 A (SEA) 介导的 T 细胞对 Caki-2 和 Raji 细胞的 EC50 分别为 20 和 30000 pM[1]。 Naptumomab estafenatox (0.001-10000 pM；4 小时) 对 SEA/E-120 介导的 T 细胞对 Caki-2 和 Raji 细胞的 EC50 分别为 0.1 和 100000 pM[1]。 Naptumomab estafenatox (1 pM-1 μM；4 天) 剂量依赖性地诱导人淋巴细胞增殖[1]。 Cell Proliferation Assay[1] Cell Line: Human peripheral blood mononuclear cell (PBMC) line Concentration: 1 pM-1 μM Incubation Time: 4 days Result: Dose-dependently induced proliferation of human PBMCs but more concentrations were needed compared with SEAwt (C242Fab-SEA) and anatumomab mafenatox. |
| In Vivo | Naptumomab estafenatox (0.016 mg；静脉注射，每日 1 次，共 8 天) 对有 Calu-1 肿瘤的免疫缺陷小鼠具有抗肿瘤作用[1]。 Animal Model: SCID mice with Calu-1 tumors and PBMC injection[1] Dosage: 0.016 mg Administration: Intravenous injection, 0.016 mg, daily injection for 8 days Result: Significantly reduced the tumor mass. |
| References |
| No Any Chemical & Physical Properties |